Akinsanya Karen (CIK 1797672) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-21). Recent activity: Buy SDGR (31,599 shares), Sell SDGR (10,000 shares), Sell SDGR (21,599 shares), Sell SDGR (1,366 shares), Buy SDGR (24,250 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Buy | 31,599 | $137,140 |
| 2026-09-21 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Sell | 10,000 | $280,000 |
| 2026-09-21 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Sell | 21,599 | $647,970 |
| 2026-03-06 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Sell | 1,366 | $17,621 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Buy | 24,250 | $0 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Buy | 6,077 | $0 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Buy | 27,576 | $0 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Sell | 2,206 | $26,450 |
| 2025-04-15 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | Buy | 13,378 | $43,077 |
| 2025-04-15 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | Buy | 3,345 | $9,767 |
| 2025-04-15 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | Sell | 8,378 | $210,372 |
| 2025-04-15 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | Sell | 5,000 | $125,550 |
| 2025-04-15 | Schrodinger, Inc. (SDGR) | President of R&D, Therapeutics | Sell | 3,345 | $83,625 |
来源：SEC Form 4 申报文件 · 截至 2026-09-21